Patient Taking Novartis AG (NVS) MS Pill Developed Rare Disease
7/30/2013 7:12:51 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
A patient taking Novartis' multiple sclerosis pill Gilenya developed a rare and potentially fatal viral disease, the Swiss drugmaker said on Tuesday, an unexpected setback as it faces growing competition from new oral treatments. Gilenya is one of Novartis' big new drug hopes, growing 66 percent in the second quarter to $468 million. But the drug faces competition from new medicines such as Biogen Idec's Tecfidera.
Help employers find you! Check out all the jobs and post your resume.
comments powered by